| 臺大學術典藏 |
2022-09-20T06:48:44Z |
In-hospital implementation of evidence-based, medications is associated with improved survival, in diabetic patients with acute coronary, syndrome - Data from TSOC ACS-DM registry
|
Chen K.-C.; Yin W.-H.; Wu C.-C.; Chan S.-H.; Wu Y.-W.; Wang K.Y.; Chang K.-C.; HWANG, JUEY-JEN; Voon W.-C.; Hsieh I.-C.; Chong J.-T.; Lin W.-S.; Hsu C.-N.; Ueng K.-C.; Hsia C.-P.; Liu J.-C.; Yeh J.-S.; Mar G.-Y.; Shih J.-Y.; Kuo J.-Y.; Tsao H.-M.; Tseng W.-K.; Yang C.-H.; Chang C.-C.; Chiang C.-E.; Lei M.-H.; Lin J.-F.; Shyu K.-G. |
| 臺大學術典藏 |
2022-09-16T08:49:07Z |
Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel
|
Huang J.-W.; CHING-HUA KUO; Kuo H.-C.; Shih J.-Y.; Tsai T.-W.; Chang L.-C. |
| 臺大學術典藏 |
2022-09-16T03:42:12Z |
Digital infarcts showing microangiopathy in adult dermatomyositis suggest severe pulmonary involvement and poor prognosis [3]
|
Tjiu J.-W.; SUNG-JAN LIN; Wang L.-F.; Shih J.-Y.; Yu C.-J.; Liang C.-W.; Chu C.-Y. |
| 臺大學術典藏 |
2022-09-15T01:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:54Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Chia-Chi Lin; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-09-13T08:19:02Z |
In-hospital implementation of evidence-based, medications is associated with improved survival, in diabetic patients with acute coronary, syndrome - Data from TSOC ACS-DM registry
|
Chen K.-C.; Yin W.-H.; CHIH-CHENG WU; Chan S.-H.; Wu Y.-W.; Wang K.Y.; Chang K.-C.; Hwang J.-J.; Voon W.-C.; Hsieh I.-C.; Chong J.-T.; Lin W.-S.; Hsu C.-N.; Ueng K.-C.; Hsia C.-P.; Liu J.-C.; Yeh J.-S.; Mar G.-Y.; Shih J.-Y.; Kuo J.-Y.; Tsao H.-M.; Tseng W.-K.; Yang C.-H.; Chang C.-C.; Chiang C.-E.; Lei M.-H.; Lin J.-F.; Shyu K.-G. |
| 臺大學術典藏 |
2022-08-19T00:21:13Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Shih J.-Y.; CHIUN HSU; Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-08-19T00:21:10Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Yang P.-C.; Chang G.-C.; CHIUN HSU; Gow C.-H.; Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P. |
| 臺大學術典藏 |
2022-08-19T00:21:08Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
Chen J.-P.; Lo Y.; Yu C.-J.; CHIUN HSU; Shih J.-Y.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
CHIUN HSU; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-12T06:28:17Z |
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells
|
Su J.-L.; Yang P.-C.; Shih J.-Y.; Yang C.-Y.; Wei L.-H.; Hsieh C.-Y.; Chou C.-H.; Jeng Y.-M.; Wang M.-Y.; KING-JEN CHANG; Hung M.-C.; Kuo M.-L. |
| 臺大學術典藏 |
2022-08-12T06:28:09Z |
The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells (DOI:10.1016/j.ccr.2006.02.018)
|
Su J.-L.; Yang P.-C.; Shih J.-Y.; Yang C.-Y.; Wei L.-H.; Hsieh C.-Y.; Chou C.-H.; Jeng Y.-M.; Wang M.-Y.; KING-JEN CHANG; Hung M.-C.; Kuo M.-L. |
| 臺大學術典藏 |
2022-08-12T06:28:02Z |
The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells (DOI:10.1016/j.ccr.2006.02.018)
|
Su J.-L.; Yang P.-C.; Shih J.-Y.; Yang C.-Y.; Wei L.-H.; Hsieh C.-Y.; Chou C.-H.; Jeng Y.-M.; Wang M.-Y.; KING-JEN CHANG; Hung M.-C.; Kuo M.-L. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-08-10T02:37:41Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; Yu C.-J.; CHIH-HSIN YANG; Shih J.-Y. |
| 臺大學術典藏 |
2022-08-10T02:37:40Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; CHIH-HSIN YANG; Shih J.-Y.; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2022-06-29T02:53:22Z |
Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer
|
Chang, L-K; Kuo, Y-W; SHANG-GIN WU; Chung, K-P; Shih, J-Y |
| 臺大學術典藏 |
2022-06-27T07:07:54Z |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
|
Wu J.-Y.; CHONG-JEN YU; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:54Z |
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
|
Wu S.-G.; Gow C.-H.; CHONG-JEN YU; Chang Y.-L.; Yang C.-H.; Hsu Y.-C.; Shih J.-Y.; Lee Y.-C.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern
|
Wu S.-G.; Chang Y.-L.; Hsu Y.-C.; Wu J.-Y.; Yang C.-H.; CHONG-JEN YU; Tsai M.-F.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:51Z |
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
|
Gow C.-H.; Chang Y.-L.; Hsu Y.-C.; Tsai M.-F.; Wu C.-T.; CHONG-JEN YU; Yang C.-H.; Lee Y.-C.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2022-06-27T07:07:49Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; CHONG-JEN YU; Cheng A.-L.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:47Z |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
|
Wu J.-Y.; Shih J.-Y.; Yang C.-H.; Chen K.-Y.; Ho C.-C.; CHONG-JEN YU; Yang P.-C. |
